BACKGROUND: Membrane cofactor protein CD46 attenuates the complement cascade by facilitating cleavage of C3b and C4b. In solid organ xenotransplantation, organs expressing CD46 have been shown to resist hyperacute rejection. However, the incremental value of human CD46 expression for islet xenotransplantation remains poorly defined. METHODS: This study attempted to delineate the role of CD46 in early neonatal porcine islet engraftment by comparing Gal-knocked out (GKO) and hCD46-transgenic (GKO/CD46) islets in a dual transplant model. Seven rhesus macaques underwent dual transplant and were sacrificed at 1 hour (n = 4) or 24 hours (n = 3). Both hemilivers were recovered and fixed for immunohistochemistry (CD46, insulin, neutrophil elastase, platelet, IgM, IgG, C3d, C4d, CD68, Caspase 3). Quantitative immunohistochemical analysis was performed using the Aperio Imagescope. RESULTS: Within 1 hour of intraportal infusion of xenografts, no differences were observed between the two types of islets in terms of platelet, antibody, or complement deposition. Cellular infiltration and islet apoptotic activity were also similar at 1 hour. At 24 hours, GKO/CD46 islets demonstrated significantly less platelet deposition (P = 0.01) and neutrophil infiltration (P = 0.01) compared to GKO islets. In contrast, C3d (P = 0.38) and C4d (P = 0.45) deposition was equal between the two genotypes. CONCLUSIONS: Our findings suggest that expression of hCD46 on NPIs potentially provides a measurable incremental survival advantage in vivo by reducing early thrombo-inflammatory events associated with instant blood-mediated inflammatory reaction (IBMIR) following intraportal islet infusion.
BACKGROUND:Membrane cofactor proteinCD46 attenuates the complement cascade by facilitating cleavage of C3b and C4b. In solid organ xenotransplantation, organs expressing CD46 have been shown to resist hyperacute rejection. However, the incremental value of humanCD46 expression for islet xenotransplantation remains poorly defined. METHODS: This study attempted to delineate the role of CD46 in early neonatal porcine islet engraftment by comparing Gal-knocked out (GKO) and hCD46-transgenic (GKO/CD46) islets in a dual transplant model. Seven rhesus macaques underwent dual transplant and were sacrificed at 1 hour (n = 4) or 24 hours (n = 3). Both hemilivers were recovered and fixed for immunohistochemistry (CD46, insulin, neutrophil elastase, platelet, IgM, IgG, C3d, C4d, CD68, Caspase 3). Quantitative immunohistochemical analysis was performed using the Aperio Imagescope. RESULTS: Within 1 hour of intraportal infusion of xenografts, no differences were observed between the two types of islets in terms of platelet, antibody, or complement deposition. Cellular infiltration and islet apoptotic activity were also similar at 1 hour. At 24 hours, GKO/CD46 islets demonstrated significantly less platelet deposition (P = 0.01) and neutrophil infiltration (P = 0.01) compared to GKO islets. In contrast, C3d (P = 0.38) and C4d (P = 0.45) deposition was equal between the two genotypes. CONCLUSIONS: Our findings suggest that expression of hCD46 on NPIs potentially provides a measurable incremental survival advantage in vivo by reducing early thrombo-inflammatory events associated with instant blood-mediated inflammatory reaction (IBMIR) following intraportal islet infusion.
Authors: W Bennet; B Sundberg; Z Song; G Elgue; L Wennberg; A Richards; D J White; R Larsson; B Nilsson; C Groth; O Korsgren Journal: Transplant Proc Date: 2000-08 Impact factor: 1.066
Authors: Jose L Estrada; Greg Martens; Ping Li; Andrew Adams; Kenneth A Newell; Mandy L Ford; James R Butler; Richard Sidner; Matt Tector; Joseph Tector Journal: Xenotransplantation Date: 2015-03-01 Impact factor: 3.907
Authors: K P Samy; R P Davis; Q Gao; B M Martin; M Song; J Cano; A B Farris; A McDonald; E K Gall; C R Dove; F V Leopardi; T How; K D Williams; G R Devi; B H Collins; A D Kirk Journal: Am J Transplant Date: 2017-12-28 Impact factor: 8.086
Authors: J S Shin; J M Kim; J S Kim; B H Min; Y H Kim; H J Kim; J Y Jang; I H Yoon; H J Kang; J Kim; E S Hwang; D G Lim; W W Lee; J Ha; K C Jung; S H Park; S J Kim; C G Park Journal: Am J Transplant Date: 2015-06-10 Impact factor: 8.086
Authors: Björn Petersen; Wolf Ramackers; Andreas Tiede; Andrea Lucas-Hahn; Doris Herrmann; Brigitte Barg-Kues; Wolfgang Schuettler; Lars Friedrich; Reinhard Schwinzer; Michael Winkler; Heiner Niemann Journal: Xenotransplantation Date: 2009 Nov-Dec Impact factor: 3.907
Authors: L Moberg; H Johansson; A Lukinius; C Berne; A Foss; R Källen; Ø Østraat; K Salmela; A Tibell; G Tufveson; G Elgue; K Nilsson Ekdahl; O Korsgren; B Nilsson Journal: Lancet Date: 2002 Dec 21-28 Impact factor: 79.321
Authors: Qimeng Gao; Robert Davis; Zachary Fitch; Michael Mulvihill; Brian Ezekian; Paul Schroder; Robin Schmitz; Mingqing Song; Frank Leopardi; Marianna Ribeiro; Allison Miller; Dimitrios Moris; Brian Shaw; Kannan Samy; Keith Reimann; Kyha Williams; Bradley Collins; Allan D Kirk Journal: Xenotransplantation Date: 2021-11 Impact factor: 3.907
Authors: Mingqing Song; Zachary W Fitch; Kannan P Samy; Benjamin M Martin; Qimeng Gao; Robert Patrick Davis; Francis V Leopardi; Niki Huffman; Robin Schmitz; Gayathri R Devi; Bradley H Collins; Allan D Kirk Journal: Xenotransplantation Date: 2021-02-22 Impact factor: 3.907